Schorndorf facility expansion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent Pharma Solutions continues to expand its drug development and delivery capabilities to help customers bring better treatments to patients through innovative controlled release technologies, with significant investments at its Schorndorf, Germany facility. Highlights of the recent expansion include the addition of R&D and commercial scale fluid bed technology, OptiMeltTM hot melt extrusion and elevated cGMP compliance for handling of OEB class 3 customer products.

With these capabilities, Catalent Schorndorf is now even better positioned to deliver solutions to their customers’ most difficult bioavailability, controlled release or targeted delivery profile challenges.

The Schorndorf expansion follows recent investments in OSDrC®  OptiDoseTM controlled release dose delivery at Catalent’s Winchester, Kentucky, US facility and Lyopan® fast-dissolve lyophilized tablet technology, underlining Catalent’s commitment to innovation and furthering its position as the industry’s leading global partner in oral drug delivery technologies. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs more than 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue.Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
FindPharma Custom Search

Click here